The following drug updates are listed by booklet title. This information is not found in the current version of these booklets, as these treatments were not FDA approved at the time the books were published.
Hodgkin lymphoma
The following treatments for Hodgkin lymphoma have been approved since the publication of Hodgkin Lymphoma.
- In November 2022, the Food and Drug Administration (FDA) approved brentuximab vedotin (Adcetris®) for the treatment of pediatric patients 2 years and older with previously untreated high risk classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide.
Non-Hodgkin lymphoma
The following treatments for Hodgkin lymphoma have been approved since the publication of Non-Hodgkin Lymphoma.
- In June 2023, the Food and Drug Administration (FDA) approved glofitamab-gxbm (Columvi™) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two or more lines of systemic therapy.
- In May 2023, the Food and Drug Administration (FDA) approved epcoritamab-bysp (Epkinly™) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy.
- In April 2023, the Food and Drug Administration (FDA) approved polatuzumab vedotin-piiq (Polivy®) in combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index score of 2 or greater.
- In April 2023, the Food and Drug Administration (FDA) removed its accelerated approval of ibrutinib (Imbruvica®) for the treatment of
- Patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
- Marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy.
- In January 2023, the Food and Drug Administration (FDA) approved pirtobrutinib (Jaypirca™) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor.
This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. - In January 2023, the Food and Drug Administration (FDA) approved zanubrutinib (Brukinsa®) for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
- In December 2022, the Food and Drug Administration (FDA) approved mosunetuzumab-axgb (Lunsumio™) for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). - In September 2022, the Food and Drug Administration (FDA) removed its approval of duvelisib (Copiktra®) for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least 2 prior therapies.
The following treatments for Hodgkin lymphoma have been approved since the publication of The Lymphoma Guide: Information for Patients and Caregivers.
- In June 2023, the Food and Drug Administration (FDA) approved glofitamab-gxbm (Columvi™) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two or more lines of systemic therapy.
- In April 2023, the Food and Drug Administration (FDA) approved polatuzumab vedotin-piiq (Polivy®) in combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index score of 2 or greater.
- In April 2023, the Food and Drug Administration (FDA) removed its accelerated approval of ibrutinib (Imbruvica®) for the treatment of
- Patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
- Marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy.
- In January 2023, the Food and Drug Administration (FDA) approved pirtobrutinib (Jaypirca™) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor.
This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. - In January 2023, the Food and Drug Administration (FDA) approved zanubrutinib (Brukinsa®) for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
- In December 2022, the Food and Drug Administration (FDA) approved mosunetuzumab-axgb (Lunsumio™) for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). - In November 2022, the Food and Drug Administration (FDA) approved brentuximab vedotin (Adcetris®) for the treatment of pediatric patients two years and older with previously untreated high risk classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide.
- In September 2022, the Food and Drug Administration (FDA) removed its approval of duvelisib (Copiktra®) for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies.